ASCO 2023 | Treatment strategies for KRAS-mutant NSCLC with co-mutations

Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, discusses management options for patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) with co-mutations. The presence of co-mutations such as STK11 and KEAP1 worsens outcomes, and the CodeBreak 200 trial (NCT04303780) showed that sotorasib does not improve outcomes in patients with co-mutations. Regimens such as nivolumab and ipilimumab, or durvalumab and tremelimumab from the CheckMate 9LA (NCT03215706) and POSEIDON (NCT03164616) trials respectively have been suggested as potential treatment strategies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.